Prediction: This Is What Eli Lilly Stock Will Do Next

Motley Fool07-26

Eli Lilly has been a favorite among pharmaceutical stock investors thanks to its success in the GLP-1 space. With the stock closing in on $900 per share, I think there is a case to be made for ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2454343921?lang=en_US&edition=fundamental","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F784274%2Fgettyimages-1978065812.jpg&op=resize&w=165&h=104","is_english":true,"pubTime":"2024-07-26 19:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2454343921","market":"us","top_or_hot":-1,"title":"Prediction: This Is What Eli Lilly Stock Will Do Next","media":"Motley Fool","content":"<div>\n<p>Eli Lilly has been a favorite among pharmaceutical stock investors thanks to its success in the GLP-1 space.\n\n\n\n\n\n\n\nWith the stock closing in on $900 per share, I think there is a case to be made for ...</p>\n\n<a href=\"https://www.fool.com/investing/2024/07/26/prediction-this-is-what-eli-lilly-stock-will-do/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Prediction: This Is What Eli Lilly Stock Will Do Next</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrediction: This Is What Eli Lilly Stock Will Do Next\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-26 19:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2024/07/26/prediction-this-is-what-eli-lilly-stock-will-do/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Eli Lilly has been a favorite among pharmaceutical stock investors thanks to its success in the GLP-1 space.\n\n\n\n\n\n\n\nWith the stock closing in on $900 per share, I think there is a case to be made for ...</p>\n\n<a href=\"https://www.fool.com/investing/2024/07/26/prediction-this-is-what-eli-lilly-stock-will-do/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1623119135.USD","symbol_name":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","start_time":0,"source_url":"https://www.fool.com/investing/2024/07/26/prediction-this-is-what-eli-lilly-stock-will-do/","article_id":"2454343921","we_media_id":null,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F784274%2Fgettyimages-1978065812.jpg&op=resize&w=165&h=104"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2454343921","pubTimestamp":1721994300,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Shares of Eli Lilly are up more than 130% in the past year, but this company's moves are far from finished.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0058720904.USD":"联博国际健康护理基金A","NVO":"诺和诺德","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","BK4585":"ETF&股票定投概念","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","BK4534":"瑞士信贷持仓","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0097036916.USD":"贝莱德美国增长A2 USD","CMG":"墨式烧烤","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LLY":"礼来","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","BK4588":"碎股","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0882574139.USD":"富达环球消费行业基金A ACC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","BK4581":"高盛持仓","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU0238689110.USD":"贝莱德环球动力股票基金","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0385154629.USD":"贝莱德营养科学基金A2","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc"},"translate_title":"预测：这就是礼来公司股票下一步的走势","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1,"NVO":0.8,"CMG":0.6},"content_text":"Eli Lilly has been a favorite among pharmaceutical stock investors thanks to its success in the GLP-1 space.\n\n\n\n\n\n\n\nWith the stock closing in on $900 per share, I think there is a case to be made for a stock split ahead.\n\n\n\n\n\n\n\nRegardless, there are good reasons to like this pharmaceutical giant and its prospects now.\n\nOver the last 18 months, the stock market has been incredibly generous to investors. Since January 2023, the S&P 500 has soared 45%, while the tech-heavy Nasdaq Composite has rocketed by 72%.Outside of the technology industry, investors have also found outsize gains among some opportunities in the pharmaceutical space. One company that has outpaced both the S&P 500 and Nasdaq since last January is Eli Lilly (LLY -4.50%). Shares of the medicine company have soared 136% since the beginning of 2023, thanks in large part to Lilly's dominance in the red-hot weight-loss space.With a stock price of almost $900 per share, I think Lilly could make a good candidate for a stock split. Let's dig into what is fueling Lilly's business right now and why a stock split could make sense. Moreover, let's see if investing in Eli Lilly stock now is a good idea.What is fueling Lilly stock right now?Eli Lilly is a diversified drug company that manufactures insulin for patients with diabetes, treatments for cancer patients, for plaque psoriasis and psoriatic arthritis, and more.Right now, Lilly's business is witnessing abnormal levels of growth thanks to the company's progress in the weight-loss space. Lilly is the maker of diabetes medication Mounjaro. For now, Mounjaro is considered to be the primary competitor to Novo Nordisk's Ozempic. In addition, Lilly makes Zepbound -- a glucagon-like peptide-1 (GLP-1) used to treat obesity.The Food and Drug Administration (FDA) approved Mounjaro back in May 2022. Despite being relatively new to the market, though, Mounjaro became Lilly's second-largest source of revenue last year, generating $5.2 billion in sales during 2023. Demand for the blockbuster drug is continuing to soar, as Mounjaro is currently on a $7.2 billion revenue run rate for 2024.While the current picture for Lilly is encouraging, investors should be thinking about the company's longer-term potential. Research from JP Morgan suggests that the GLP-1 market could be worth $100 billion by 2030. Given Lilly's current revenue from its GLP-1 treatments, the potential size of the market suggests that much more growth could be in store.Furthermore, some GLP-1 treatments such as Wegovy have already been granted expanded indications from the FDA. Given these developments, it's not surprising to see Lilly exploring additional treatment areas for Mounjaro. The subtle idea here is that the proliferation of GLP-1 medications outside of diabetes and weight loss could mean that the overall market size for these treatments is well above JP Morgan's forecasts.On top of its GLP-1 business, Lilly recently made another major stride. The company received FDA approval for its Alzheimer's disease medication, donanemab. Not only does this further deepen Lilly's already impressive roster of medications, but it opens the door to yet another multibillion-dollar industry.Image source: Getty Images.Could Eli Lilly split its stock?Given all of the information above, it's not entirely surprising to see why Lilly's stock has been on a tear. In 2024 alone, shares have gained 51%, handily outperforming the broader market.But with such incredible momentum fueling the stock, it's appropriate to posit the idea of a stock split. In recent years, many large companies that witnessed outsize stock gains have performed stock splits. Some examples include Nvidia, Tesla, Amazon, Alphabet, Walmart, and Chipotle Mexican Grill.Even Lilly's closest competitor, Novo Nordisk, completed a 2-for-1 stock split last September. Considering the high price tag for just one share of Lilly stock, some investors may be discouraged and decide to look for alternatives.Is Eli Lilly a good stock to buy right now?Understanding how stock splits work is important. During a split, the number of outstanding shares increases by the multiple in the split. At the same time, the share price falls by the same ratio.This means that stock splits do not actually change the underlying market cap of a company. Rather, shares are simply perceived as less expensive given the lower stock price. Nevertheless, companies often opt for stock splits as the lower share price opens up buying activity to a broader base of investors.It's crucial for investors to realize that my prediction for a split is speculation. While I think there is a good case to be made for a stock split, there is no guarantee that it will happen anytime soon -- or at all.The bigger lesson for investors is that a high stock price should not deter you from building a position in a well-run company with good prospects. In Lilly's case, the company is rapidly disrupting a major new part of the healthcare space (i.e., weight loss), and the long-term outlook suggests that Lilly's growth in the diabetes and obesity-care realms is just beginning.Moreover, now with the company set to enter the Alzheimer's market, Lilly is even better positioned to continue growing across many different areas in the medical space. To me, Lilly stock is a compelling opportunity for long-term investors, and I think now is a great time to scoop up shares.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.26.3","shortVersion":"4.26.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2454343921"}